Comment from Amgen

Summary: Amgen, a global biotechnology and pharmaceutical company, supports the draft guidance on New Approach Methodologies (NAMs) for drug development. They request specific improvements to clarify regulatory pathways, provide practical implementation examples, expand the scope to include complex modalities and in silico data, and improve the guidance on human biological relevance and validation.